CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094334 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Angélica María Herreno-Pachón und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nemours Children's Health, Wilmington, DE 19803, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Fibroblasts, Gene Editing, Antigens, CD34. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, A Cure for Robert, Inc, Austrian MPS Society, Morquio Foundations.
Abstract (Originalsprache)
Mucopolysaccharidosis (MPS) IVA is a bone-affecting lysosomal storage disease (LSD) caused by impaired degradation of the glycosaminoglycans (GAGs) keratan sulfate (KS) and chondroitin 6-sulfate (C6S) due to deficient N-acetylgalactosamine-6-sulfatase (GALNS) enzyme activity. Previously, we successfully developed and validated a CRISPR/nCas9-based gene therapy (GT) to insert an expression cassette at the AAVS1 and ROSA26 loci in human MPS IVA fibroblasts and MPS IVA mice, respectively. In this study, we have extended our approach to evaluate the effectiveness of our CRISPR/nCas9-based GT in editing human CD34+ cells to mediate cross-correction of MPS IVA fibroblasts. CD34+ cells were electroporated with the CRISPR/nCas9 system, targeting the AAVS1 locus. The nCas9-mediated on-target donor template insertion, and the stemness of the CRISPR/nCas-edited CD34+ cells was evaluated. Additionally, MPS IVA fibroblasts were co-cultured with CRISPR/nCas-edited CD34+ cells to assess cross-correction. CRISPR/nCas9-based gene editing did not affect the stemness of CD34+ cells but did lead to supraphysiological levels of the GALNS enzyme. Upon co-culture, MPS IVA fibroblasts displayed a significant increase in the GALNS enzyme activity along with lysosomal mass reduction, pro-oxidant profile amelioration, mitochondrial mass recovery, and pro-apoptotic and pro-inflammatory profile improvement. These results show the potential of our CRISPR/nCas9-based GT to edit CD34+ cells to mediate cross-correction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nemours Children's Health, Wilmington, DE 19803, USA.
- Faculty of Arts and Sciences, University of Delaware, Newark, DE 19716, USA.
- Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, DC, Colombia.
- Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan.
- Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA.
ORCID-Profile: Angélica María Herreno-Pachón, Andrés Felipe Leal, Carlos Javier Alméciga-Díaz, Shunji Tomatsu
Förderung
- NIH HHS
- A Cure for Robert, Inc
- Austrian MPS Society, Morquio Foundations
- Institutional Development Award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Zitieren
APA
Herreno-Pachón, A. M., Leal, A. F., Khan, S., Alméciga-Díaz, C. J., & Tomatsu, S. (2025). CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094334
Vancouver
Herreno-Pachón AM, Leal AF, Khan S, Alméciga-Díaz CJ, Tomatsu S. CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094334
BibTeX
@article{HerrenoPachn2025,
author = {Herreno-Pachón, Angélica María and Leal, Andrés Felipe and Khan, Shaukat and Alméciga-Díaz, Carlos Javier and Tomatsu, Shunji},
title = {CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094334}
}
EUVIMED